The article discusses how significant cuts to US funding for global HIV initiatives, initiated during Donald Trump's second presidential term, threaten progress in the fight against HIV infections. While lenacapavir, a new preventative drug, has been hailed as a major breakthrough, experts suggest that reduced support for domestic health institutions and foreign aid projects could jeopardize the ability to effectively distribute this treatment. The concern is whether this advancement can be fully realized without sustained funding for comprehensive health agencies.
Experts warn that cuts to US domestic health funding and foreign aid under Trump's second term may undermine efforts against rising HIV infections.
Despite the approval of lenacapavir as a preventive drug for HIV, experts worry funding cuts will hinder essential public health initiatives.
Collection
[
|
...
]